Update on the treatment of phenylketonuria: long-term safety and efficacy of sapropterin dihydrochloride

References

• Jervis GA. Phenylpyruvic oligophrenia deficiency of phenylalanine- oxidizing system. Proc Soc Exp Biol Med. 1953;82(2):514–515.
   Google Scholar
• Bickel H. The effects of a phenylalanine-free and phenylalanine-poor diet in phenylpyruvic oligophrenis. Exp Med Surg. 1954;12(1):114–117.
   Google Scholar
• Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 1963;32(3):338–343.
   PubMed Web of Science ®Google Scholar
• Smith I, Lobascher ME, Stevenson JE, et al. Effect of stopping low-phenylalanine diet on intellectual progress of children with phenylketonuria. Br Med J. 1978;2(6139):723–726.
   Google Scholar
• VanZutphen KH, Packman W, Sporri L, et al. Executive functioning in children and adolescents with phenylketonuria. Clin Genet. 2007;72(1):13–18.
   PubMed Web of Science ®Google Scholar
• Koch R, Burton B, Hoganson G, et al. Phenylketonuria in adulthood: a collaborative study. J Inherit Metab Dis. 2002;25(5):333–346.
   Web of Science ®Google Scholar
• Levy HL, Waisbren SE. PKU in adolescents: rationale and psychosocial factors in diet continuation. Acta Paediatr. 1994;407:92–97.
   Google Scholar
• Koch R, Hanley W, Levy H, et al. The Maternal Phenylketonuria International Study 1984–2002. Pediatrics. 2003;112(6 pt 2):1523–1529.
   Google Scholar
• Hyland K, Cotton RH, Thony B, Blau N. Disorders of tetrahydrobiop- terin and related biogenic amines. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, editors. The Online Metabolic and Molecular Bases of Inherited Disease. Available at http://www.ommbid.com/. Accessed Sep 2012.
   Google Scholar
• Kure S, Hou DC, Ohura T, et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr. 1999;135(3):375–378.
   PubMed Web of Science ®Google Scholar
• Curtius H, Wiederwieser C, Viscontini G, Leimbacher N, Wegman H, Schmidt H. Serotonin and dopamine synthesis in phenylketonuria. Adv Exp Med Biol. 1981;133:277–291.
   Google Scholar
• Puglisi-Allegra S, Cabib S, Pascucci T, Ventura R, Cali F, Romano V Dramatic brain aminergic deficit in a genetic mouse model of phenylketonuria. Neuroreport. 2000;11(6):1361–1364.
   Web of Science ®Google Scholar
• Ormazabal A, Vilaseca MA, Perez-Duenas B, et al. Platelet serotonin concentrations in PKU patients under dietary control and tetrahydro- biopterin treatment. J Inherit Metab Dis. 2005;28(6):863–870.
   Google Scholar
• Erlandsen H, Pey AL, Gamez A, et al. Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc Natl Acad Sci U S A. 2004;101(48):16902–16908.
   Web of Science ®Google Scholar
• Bjorgo E, de Carvalho RM, Flatmark T. A comparison of kinetic and regulatory properties of the tetrameric and dimeric forms of wildtype and Thr427-->Pro mutant human phenylalanine hydroxylase: contribution of the flexible hinge region Asp425-Gln429 to the tetramerization and cooperative substrate binding. Eur J Biochem. 2001;268(4):997–1005.
   Google Scholar
• Karacic I, Meili D, Sarnavka V et al. Genotype predicted tetrahydro- biopterin (BH4)-responsiveness and molecular genetics in Croatian patients with phenylalanine hydroxylase (PAH) deficiency. Mol Genet Metab. 2009;97(3):165–171.
   PubMed Web of Science ®Google Scholar
• Sarafoglou K, Hoffman G, Roth K. Pediatric Endocrinology and In born Errors of Metabolism. New York, NY: McGraw-Hill; 2008.
   Google Scholar
• Utz J, Lorentz C, Markowitz D, et al. START, a double blind placebocontrolled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients. Mol Genet Metab. 2012;105(2):193–197.
   Web of Science ®Google Scholar
• Dubrowski S, Heintz C, Miller T, et al. Molecular genetics and impact of residual in vitro phenylalanine hydroxylase activity on tetrahydro- biopterin responsiveness in Turkish PKU population. Mol Genet Metab. 2011;102(2):116–121.
   Web of Science ®Google Scholar
• Burton BK, Grange DK, Milanowski G, et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J Inherit Metab Dis. 2007;30(5):700–777.
   Web of Science ®Google Scholar
• Levy H, Milanowski A, Chakrapani A, et al; Sapropterin Research Group. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomized clinical placebo-controlled study. Lancet 2007;370(9586):504–510.
   PubMed Web of Science ®Google Scholar
• Lee P, Treacy E, Crombex W, et al. Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am J Med Genet. 2008;146A(22):2851–2859.
   PubMed Web of Science ®Google Scholar
• Tretz FK, Burtin BK, Longo N, et al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a Phase III, randomized, double-blind, placebo controlled study. J Pediatr. 2009;154(5):700–707.
   Web of Science ®Google Scholar
• Burton B, Nowacka M, Hennermann JB, et al. Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: Results of a phase 3b study. Mol Genet Metab. 2011;103(4):315–322.
   Web of Science ®Google Scholar
• Vernon HJ, Koerner CB, Johnson MR, Bergner A, Hamosh A. Introduction of sapropterin dihydrochloride as standard of care in patients with phenylketonuria. Mol Genet Metab. 2010;100(3):229–233.
   Web of Science ®Google Scholar
• Blau N, Hennermann J, Langenbeck U, Lickter-Konecki U. Diagnosis, classification and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab. 2011;104 Suppl:S2-S9.
   Web of Science ®Google Scholar
• Fiege B, Bonafe L, Ballhausen D, et al. Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: a pilot study. Mol Genet Metab. 2005;86(S1):91–95.
   Google Scholar
• Burton BK, Adams DJ, Grange DK, et al. Tetrahydrobiopterin therapy for phenylketonuria in infants and young children. J Pediatr. 2011;158(3):410–415.
   PubMed Web of Science ®Google Scholar
• Koch R. Maternal phenylketonuria and tetrahydrobiopterin. Pediatrics. 2008;122(6):1367–1368.
   Web of Science ®Google Scholar
• Koch R, Moseley K, Guttler F. Tetrahydrobiopterin and maternal PKU. Mol Genet Metab. 2005;86(Suppl 1):S139-S141.
   Google Scholar
• Lee PJ, Amos A, Robertson L, et al. Adults with late diagnosed PKU and severe challenging behaviour: a randomised placebo-controlled trial of a phenylalanine-restricted diet. J Neurol Neurosurg Psychiatry. 2009;80(6):631–635.
   Web of Science ®Google Scholar
• Grosse SD. Late-treated phenylketonuria and partial reversibility of intellectual impairment. Child Dev. 2010;81(1):200–211.
   Web of Science ®Google Scholar